Table 1.
Characteristics | DHLI group (n = 45) |
SKYD group (n = 45) |
P value |
---|---|---|---|
Male | 26 (57.8) | 21 (45.7) | 0.291 |
Age-year | 39.0 ± 8.6 | 36.6 ± 8.9 | 0.192 |
Medication history | |||
SASP | 5 (11.11) | 6 (13.33) | 1.000 |
5-ASA | 19 (42.22) | 21 (46.67) | 0.416 |
TCM | 11 (24.45) | 7 (15.56) | 0.430 |
Integrative treatment | 10 (22.22) | 11 (24.45) | 1.000 |
Disease type | |||
Initial onset type# | 13 (28.9) | 2 (3.4) | 0.002 |
Chronic persistent type | 15 (33.3) | 19 (42.2) | 0.384 |
Chronic relapsing type | 17 (37.8) | 24 (53.3) | 0.138 |
Active phase# | 31 (68.9) | 19 (42.2) | 0.011 |
Remission phase# | 14 (31.1) | 26 (57.7) | 0.011 |
Disease level | |||
Mild | 12 (26.7) | 16 (35.6) | 0.362 |
Middle | 29 (64.5) | 28 (62.2) | 0.827 |
Severe | 4 (6.9) | 1 (2.2) | 0.167 |
Duration of disease | |||
⩽60 months# | 19 (42.2) | 10 (22.2) | 0.042 |
>60 months# | 26 (57.8) | 35 (77.8) | 0.042 |
Clinical activity index# | 7.4 ± 2.3 | 6.4 ± 2.1 | 0.036 |
Endoscopic index# | 6.0 ± 2.2 | 4.8 ± 1.7 | 0.010 |
Biopsy type☆ | |||
0 | 8 (17.8) | 11 (24.4) | 0.438 |
1 | 10 (22.2) | 8 (17.8) | 0.598 |
2 | 12 (26.7) | 13 (28.9) | 0.814 |
3 | 8 (17.8) | 7 (15.6) | 0.777 |
4 | 3 (6.7) | 4 (8.9) | 0.694 |
5 | 4 (8.9) | 2 (4.4) | 0.398 |
*Data was presented as case number (%). Age, clinical activity index, and endoscopic index were displayed as mean ± SD.
# P < 0.05. There was significant difference between the DHLI and SKYD groups.
☆0, structural change only; 1, chronic inflammation; 2, lamina propria neutrophils; 3, neutrophils in epithelium; 4, crypt destruction; and 5, erosions or ulcers [18].